Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Off-Label Immune Checkpoint Inhibitor Blockade Across Malignancies
NCT07754292Phase 2Not yet recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Nov 2026
- Primary completion
- Nov 2032
- Countries
- 1
01
Overview
Phase 2, open-label trial in malignancy (3 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Clinical response at 6 months. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
malignancy
Beyond the preview
Go deeper on NCT07754292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754292.